Why did two private equity firms with more than $460 billion under management want a little old gene therapy biotech called ...

The high court sides with HHS on HIV PrEP drugs; Health Secretary RFK Jr.’s newly appointed CDC vaccine advisors discuss ...

The safety update for Vyvgart rattled argenx’s shares on Monday, a reaction that analysts at William Blair said was “overdone ...

California’s life sciences manufacturing jobs dipped 3.7% in 2024, according to a new Biocom California report. Still, ...

As an office of the executive branch, the Department of Health and Human Services “does not have the authority” to implement ...

The women’s health focused company acquired the drug for up to $954 million in 2021 through the acquisition of Forendo Pharma ...

Kennedy wants to expand the injury compensation program to include COVID-19 vaccines, while also stretching the “statute of ...

Analysts believe that Gilead's new PrEP drug Yeztugo could reach peak sales of $4.5 billion. Not if GSK has anything to say about it.

In this episode presented by IQVIA, BioSpace's head of insights Lori Ellis discusses the FDA's first draft guidance for AI in ...

Cell and gene therapy leaders say the agency’s decision to remove the Risk Evaluation and Mitigation Strategies that had been ...

Protagonist is directly going up against Eli Lilly, which is advancing retatrutide, also a triple-G agonist, in a Phase II ...

Macrocyclic peptides are designed to engage complex targets like biologics but pass through cell membranes like small ...